^Investigational New Drug Toxicology for Drugs to Treat AD & Other Aging-Related

开发和测试治疗与阿尔茨海默病（AD）相关的认知障碍的新药是美国国家衰老研究所（NIA）的一项主要计划活动，但目前由于许多研究人员无法进入动物试验设施而受到阻碍。由于目前缺乏能够一致地减缓或逆转疾病进展、改善症状或预防疾病的任何化合物，因此需要尽一切努力促进新化合物的开发和测试。开发其他与衰老有关的疾病（如骨质疏松症）的化合物的必要性也很明显。此外，用于评估AD脑β -淀粉样蛋白和其他病理生理特征的正电子发射断层扫描（PET）显像剂的出现需要在人体研究之前对这些药物进行毒理学测试。

Efforts in developing and testing new drugs for the treatment of the cognitive impairment associated with Alzheimer's disease (AD) represent a major programmatic activity of the National Institute on Aging (NIA) but are now hindered by the lack of access of many investigators to animal testing facilities. The present paucity of any compounds which can uniformly slow or reverse the progression of the disease, ameliorate the symptoms, or prevent the disease requires that every effort be made to facilitate the development and testing of new compounds. The need to develop compounds for other aging related diseases such as osteoporosis is also apparent. Additionally, the advent of Positron Emission Tomography (PET) imaging agents for assessing brain beta-amyloid and other pathophysiological features of AD requires toxicological testing of these agents prior to human studies. However, there are still gaps in our overall effort to facilitate the development and testing of new compounds. Specifically, resources are needed by investigators who are developing new compounds so that the potential adverse toxicological activity of the compounds can be evaluated before they can be taken into clinical trials. This is a very expensive process and is beyond the resources of almost all investigators. NIA program staff have been contacted by investigators who have compounds that they believe seem promising for the treatment of Alzheimer's disease and that they would like to take into clinical trials, but they do not have the resources to have the mandatory toxicological screening done.